The ortho-quinone natural product β-lapachone, which has been subjected to phase II clinical trials for cancer therapy, was shown to target USP2, resulting in induction of apoptosis in the DU-145 prostate cancer cell line [174]. The gene discussed is USP2; the disease is Familial prostate cancer.